[A case of recurrence after resection of stage IV advanced bile duct cancer responding well to S-1/cisplatin combination chemotherapy].
The patient was a 70-year-old man who in November 2000 had undergone pancreatoduodenectomy for a diagnosis of lower bile duct cancer by his previous physician. Left cervical and intra-abdominal lymph node enlargement were detected at 3 years 4 months postoperatively, and a biopsy resulted in a histopathological diagnosis of metastasis by bile duct cancer. Intravenous S-1,120 mg/body, on days 1-14, and CDDP, 20 mg/body, on day 14 was started in April 2004. It was conducted safely on an outpatient basis with no adverse events, and it was possible to achieve survival for 29 months. S-1/CDDP therapy seemed to be capable of serving as a useful treatment for gallbladder and bile duct cancer in the future.
Mori
Yasuharu
Y
Department of Surgery, Jinwakai General Hospital.
Katsumata
Kenji
K
Tokita
Hiromi
H
Kato
Fumiaki
F
Yamamoto
Junichi
J
Tsuchida
Akihiko
A
Aoki
Tatsuya
T
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001650:Bile Duct Neoplasms / Q000188:drug therapy* / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D004338:Drug Combinations; D006801:Humans; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010094:Oxonic Acid / Q000008:administration & dosage; D016577:Pancreaticoduodenectomy; D005641:Tegafur / Q000008:administration & dosage
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin